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Abstract  
Background 
The review was carried out review prior to evaluating and to inform our research on the  
clinical pharmacists in general practices pilot, a world leading initiative to improve 
health care delivery in England. Around 500 pharmacists are already working in general 
practice as part of the pilot, launched in July 2015  
Objectives 
The review attempts to explain the how “clinical pharmacists in general practices” is 
being implemented, what works well, what does not work so well and everything in-
between.  
Methods 
This realist review was conducted to the RAMESES standards. Studies were identified by 
searching three databases, Medline, Embase and Scopus. Additional papers were 
gathered from reference lists, Google searches and via the find similar citations feature.  
Results  
A total of 83 papers and articles were initially identified from Medline (19), Embase (31) 
and Scopus (32). With close reading, the final review consisted of of 43 papers relating 
to 38 studies. Most of the research was undertaken in the field of pharmacy practice and 
over half of the studies investigated the perspectives of different stakeholders using 
questionnaires or qualitative methods.  
Conclusion 
The pharmacist in general practices initiative is still at an early stage of implementation, 
further research and more in-depth findings are still required. However, from this small 
number of studies, the common barriers and facilitators to the implementation can be 
identified. The review also lists mechanisms that will be needed to ensure the effective 
implementation of this initiative.  
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Background  
The General Practice Forward View1 recognises some of the key issues in efficiently and 
effectively managing the frontline demand and supply of health care in the United Kingdom 
(UK). The ageing population and the rise in long term health conditions has impact on an 
increasing demand for Primary Care. General Practitioner (GP) consultations increased 
between 1996 and 2008 by an estimated 11%, and nurse consultations by 150%2. At the 
same time government spending on healthcare, and in particular in General Practice in 
Great Britain has declined. Furthermore, there are significant reductions in the numbers 
entering general practice as a career, and a high rate of turnover of those working in the 
profession. In 2013 the Royal Pharmaceutical Society (RPS) ‘Now or Never’ report3 
highlighted a number of new models of care through which pharmacy is delivered and 
advocated moving away from dispensing and supply, towards using the professional 
expertise of pharmacists.  The Royal College of General Practice (RCGP) agreed and 
suggested that primary care requires a more diverse skill mix and community pharmacy is a 
‘significant unexploited potential’4. In 2014 the RPS English Pharmacy Board called for GPs 
to embrace the potential that pharmacists can bring to the care of their patients; local 
commissioners to include pharmacist expertise in all care pathways that use medicines 
including the formal involvement of community pharmacists in local care pathways and NHS 
England to support the spread of good practice and the dissemination of evidence which 
shows the benefits of pharmacist input in GP surgeries5. At Clinical Commissioning Group 
(CCG) level, commissioners were encouraged to think of new, innovative and creative ways 
to solve this pressing problem and meet the increasing levels of demand with diminishing 
modes of supply6,7. 
 
The introduction of clinical pharmacists working in general practices was initiated by 
National Health Service England (NHSE) as a pilot scheme in 2015 and operationalized in 
2016-7. This pilot employs around 500 clinical pharmacists across about 90 general 
practices. Due to huge response from the GP practices, the funding for this scheme was 
doubled from £15m to £31m8. Further investment was announced in 2016 as NHS England 
plans to invest further £100m to support an additional 1,500 pharmacists by 2020/219. This 
whole scheme is part of the larger initiative to expand the primary care workforce, 
documented in the General Practice Forward View1.The GP workforce 10-point plan10 
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acknowledged that to address the supply-demand imbalances GP practices will be 
encouraged to recruit pharmacists; the report laid out plans for a national pilot launching in 
2015 with the first pharmacists working in General Practice on the pilot scheme by 2016. 
This initiative promotes a largely new role for pharmacists about which little was already 
known.  The review was carried out prior to evaluating the NHSE pilot study so was used to 
inform and frame the pilot study. It will be useful for policy makers, pharmacists and 
primary care in other countries who are watching the NHSE pilot with great interest. The 
initiative should in theory should reduce GP workload, improve patient care; and expand 
the primary care workforce. With these factors in mind, it was important to address 
whether such complex interventions work, if so, why do they work and what does not work. 
This realist review11,12 therefore explores the international research and policy on 
introducing pharmacists into general practice using a realist review perspective, in a process 
which identifies and analyses the context, mechanisms and outcomes.  
Aims  
To identify what works for whom in what circumstances in relation to the role of 
pharmacists in general practice. 
Objective  
Strategic objectives  
The review attempts to explain the outcomes of how pharmacists in GP practices is being 
implemented, what works well, what does not work so well and everything in-between.  
Operational objectives  
• Identify studies of pharmacists working in general practice. 
• Identify additional relevant publications, for example, policy documents, reports 
that contribute to theory building about what works for whom in what 
circumstances.  
• Gain familiarity with dataset by close reading. 
• Produce a descriptive summary of the data to summarize what kinds of research 
question have been asked, how these questions have been addressed and what 
the key findings are to date. 
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• Develop a realist analysis consisting of candidate theories linking context, 
mechanism and outcome.  
• Undertake systematic data extraction to test and refine these candidate theories. 
• Summaries the theories for which there is strong evidence of what works for 
whom in what circumstances. 
• Clarify gaps in the knowledge base and make recommendations for further 
research.   
Methods 
Study design  
A descriptive realist review which was conducted to the RAMESES standards11. 
Realist review 
Pawson et al.12 described realist review as “What works, for whom, in what circumstances 
and why” Health care interventions are complex and often have outcomes that are 
dependent on context. When complex health care interventions fail to achieve their desired 
outcomes, the explanation frequently provided is because they are both complex and 
context dependent. Realist reviews can help make sense of these types of interventions or 
programmes. Realist approaches are theory driven and the primary data comes from 
primary research but also from so called grey literature documents (e.g. studies, policy 
documents and so on) and so it is a form of secondary research. Realist review is a relatively 
new strategy for synthesising research and it has an explanatory rather than judgemental 
focus.  A realist review seeks to unravel the links between context, mechanism and 
outcome. The realist research question is often summarized as ‘what works for whom under 
what circumstances, to what extent, how and why’11. Unlike other literature review 
methods, realist reviews explore the complex links between how an intervention alters the 
context, then via what mechanisms it produces certain outcomes. It aims to explain the 
success, failures and everything in-between through using middle range theories’ which are 
theories that require some abstract thinking but do not differ too much from the observed 
data and thus can be used for empirical testing. This review is conducted to the RAMESES 
quality standards published by an international Delphi panel11.  
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Figure 1 Study Flow Chart  
 
Research Questions 
As is usual in a realist review, the main question of what works for whom in what 
circumstances in relation to the role of pharmacists in general practice was further broken 
down into six, sub questions and one higher-order realist question, as we carried out the 
review:  
Descriptive questions 
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1. What is the patient perspective on pharmacists working in GP practices? 
2. What is the general practitioner perspective on pharmacists working in GP 
practices?  
3. What is the pharmacist perspective on pharmacists working in GP practices?  
4. What is the impact of pharmacists on patient’s health outcomes? 
5. What are the barriers preventing the successful implementation of this role? 
6. What are the facilitators ensuring the successful implementation of this role? 
 Realist question 
How do the key mechanisms of patient trust, GP confidence and pharmacist capability 
interact with contextual influences and the model of delivery interact with one another to 
explain the successes and failures of pharmacists working in general practice? 
 
Sample 
The studies were gathered via systematically searching through three databases (Medline, 
Embase and Scopus). A snowballing technique was used to gather further papers using 
Google searches, reference lists and the search similar citations function. Though at first 
glance it seemed that there were some relevant papers related to the questions asked, 
many were deemed unrelated when the titles and abstracts were read. Of the 83 papers, 40 
were irrelevant, had significant flaws or were so small and parochial that their 
generalizability was doubted.  Afterwards close reading was undertaken. Some papers were 
not necessarily empirical studies but were editorials or articles that related and helped to 
build the foundation and structure of this review. The papers were then analyzed and 
interpreted using the 6 descriptive questions. Over half of the studies used questionnaires 
or qualitative methodology (semi structured interviews, focus groups, 
documentary/discourse analysis or observation) to seek to attain the perspectives from the 
key groups such as patients, GPs, practice managers and pharmacists. The 43 papers we 
included were from 38 different studies. We could find no relevant policy papers apart from 
the ones referred to in the introduction which were written before the pilot study took 
place.  The research questions were developed, as we read the studies and the answers to 
those questions are embedded throughout most of the studies.   
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Descriptive analysis  
To ensure rigour, all the papers were read at least twice, by two authors, before being 
entered into an excel spreadsheet. The papers were then categorized by what database 
they were obtained from. The spreadsheet aided the differentiation of which descriptive 
question/s perspectives listed above each paper explores. We included editorials and 
articles from the UK Pharmaceutical Journal, for example.  
Realist analysis  
Initially it was thought that more data on the mechanisms of the interventions, the health 
consequences and the impact the interventions have produced would be found. As we 
gathered more literature, it was clear that this data for this intervention is not yet widely 
available and published. although there is some outcome data for similar interventions in 
primary care settings in other countries or situations. However, there was little detail in any 
of the papers of the mechanisms of embedding pharmacists in general practice apart from 
those of patient trust, GP confidence and pharmacist capability. The papers did not include 
theory and were largely descriptive.   Though the data was minimal as of writing, the papers 
gathered have influenced and changed the objectives of this review. Over half of the studies 
were either questionnaires or qualitative and largely focused on the perspectives of 
stakeholders on this intervention, the review focuses more on perspectives, barriers and 
facilitators for implementation of the role. This, due to the flexibility of a realist review is a 
major theme of this review. 
Results  
A total of 83 papers and articles were initially identified from Medline (19), Embase (31) and 
Scopus (32). With close reading, the final review consisted of of 43 papers relating to 38 
studies ( See figure 1 study flow chart ) . Most of the research was undertaken in the field of 
pharmacy practice and over half of the studies investigated the perspectives of different 
stakeholders using questionnaires or qualitative methods. The results are presented as 
answers to the 6 descriptive questions and then the realist question. 
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Descriptive findings  
Questions 1: What is the patient perspective on pharmacists working in GP practices? 
Petty et al. 13 conducted extensive research looking into the views of patients on 
pharmacists conducting medication reviews in a GP setting. They concluded that not  all 
patients will benefit from medication reviews as most patients already have these reviews 
with their GPs. They found that some patients welcomed the more detailed and longer 
review but some were disappointed by the services as the pharmacists did not meet their 
unrealistic expectations of the clinic, such as hoping that the pharmacist would be able to 
stop long-term medication or cure their problem 
 
Independent prescribing pharmacists are valued by patients as an alternative to GP 
prescribing in GP practices14. However, patients had a stronger preference for their own 
doctor than a prescribing pharmacist. In an Australian study15 patients still viewed 
pharmacists as suppliers of medicines, though they welcomed the integration of 
pharmacists into GP practice, they also wished for more dispensing, therapeutic drug 
monitoring and supply of over the counter medicines.  Younger patients were more likely to 
welcome the extended roles of pharmacists16 they were more willing to have their 
pharmacist to have both prescribing and dispensing roles. An Australian study17 concluded 
that there were positive patient attitudes towards pharmacists in primary care and stated 
that patients were highly satisfied with pharmacist consultations. Green et al.18 interviewed 
seven patients in one London GP practice and they mostly found the pharmacist to be 
experienced and beneficial. The authors conclude that as better understanding of the 
pharmacist’s role might improve patient uptake. The studies above were all conducted 
before the NHS England initiative was introduced, thus the perspectives of patients in UK 
might have changed as a result of the intervention.  
 
Snell et al.19investigated patient views about a pharmacist led patient-centred 
polypharmacy medication review service completed within 17 English GP practices with 
those ≥ 75 years of age and prescribed ≥ 15 medications, during 415 consultations. Of the 
40% who returned the questionnaire, 83% found the service helpful. Medication-related 
 9 
concerns of 94% were addressed, and 80% understood their medicines better after the 
review. Patients appreciated pharmacists’ personal approach, advice and explanations. 
 
Question 2: What is the general practitioner perspective on clinical pharmacists working in 
GP practices?  
GPs are much more welcoming to the idea of a pharmacist working in their practice if the 
GP has worked with a pharmacist before20. Both GPs and pharmacists think that patients 
would accept these new services, they also agree that the initial acceptance by GPs would 
be low but would increase with further exposure21. A recent Icelandic action research 
study22 where pharmacists provided medicines reviews in either patients’ homes, or the GP 
practice, where they had access to patient records, showed that GPs’ knowledge about 
pharmacist competencies as healthcare providers and their potential in patient care 
increased. GPs said they wanted to have access to a pharmacist on a daily basis.  
 
Question 3: What is the pharmacist perspective on clinical pharmacists working in GP 
practices?  
Butterworth et al. 23 indicated an enthusiasm for the role and called for a definition of the 
role, with examples of the knowledge, skills, and attributes required, to be made available 
to pharmacists, primary care teams, and the public. The authors conclude that training 
should include clinical skills teaching, set in context through exposure to general practice, 
and delivered motivationally by primary care practitioners. Consultations with a pharmacist 
regarding medicines, in a general practice setting in the UK, have previously been reported 
to be rich in content, acceptable to patients, and perceived by pharmacists to be a possible 
way to extend their role24.  A UK analysis of audio-recorded consultations about 
medications, between patients and pharmacists in general practice, concluded that 
pharmacists were patient centred, and responded positively and effectively to patients’ 
emotional cues and concerns. The pharmacists in Butterworth’s23 study recognised the 
importance of a holistic, individualised approach to patientcare and they valued the 
communication skills training on this course. 
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Canadian pharmacists25,26 in the iMPACT study needed time to expand their knowledge and 
skills to address family practice needs. They felt their identity changed with time and that 
they became more holistic and less “black and white” in their approach. Pharmacists need 
to be prepared for the emotional challenges of becoming part of an interdisciplinary team 
and need to use integration strategies to work. Mentoring and guided integration activities 
were helpful to facilitate integration into family practice but pharmacists still experienced a 
variety of emotions in the early months27.  
 
In order to be successful in gaining patient referrals and feeling part of the team, 
pharmacists needed to be visible, communicate well and be flexible and innovative. Once 
they demonstrated their value, they felt that buy-in from doctors happened.  
This quote28 highlights the uniqueness of the role and the initial feelings 
“I’m a pharmacist so I know how to be a pharmacist. I don’t know how to be a 
pharmacist in a Family Health team because nobody knows about that yet. I walked in 
and I did pharmacy things, but I didn’t know what that meant in relation to what the 
nurse does or what the dietitian does.”  
 
Question 4: What is the impact of pharmacists in general practice on patents health 
outcomes?  
A meta-analysis of randomised controlled studies found improved medication concordance 
and reduced potential medication-related problems in general practices with an integrated 
pharmacist29. The first randomised controlled trial of pharmacist prescribing in the UK 
suggested that there may be a benefit for patients with chronic pain30.  Freeman’s 
Australian study31 shows that pharmacists improve the timeliness and the overall 
completion rate of medication reviews in general practice, the study also concludes that the 
time between referral and pharmacist consultation is reduced. The same applies to the time 
between the pharmacist consultation to GP follow-up consultation, furthermore more 
patients were getting reviewed overall. Pharmacist interventions greatly improve asthma 
control tests (ACT) and COPD assessment test (CAT) scores in asthma and Chronic 
Obstructive Pulmonary Disease (COPD) patients, they further reduced the utilization of 
healthcare services and significantly reduce drug cost32. Pharmacist consultations can be 
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highly effective in identifying and resolving medication related problems33  the same study 
also concludes that the patients welcomed these consultations and improved medication 
adherence. For high-risk patients with type 2 diabetes mellitus, proactive case management 
by a pharmacist can reduce HbA1c levels of 1.2% compare dto control in a primary care clinic 
setting34, this reduction in HbA1C levels would result in an estimated 40% to 50% relative 
reduction in microvascular complications. Patients that are seen by a pharmacist have a 
higher chance of their medication being changed compared to a control group, although the 
cost of the drug increased in both groups, the intervention group was smaller than the 
control group. The intervention did not increase the workload of general practitioners but it 
did not prove to have decreased the workload either35. Falls can be significantly reduced in 
elderly patients in care homes by clinical pharmacist medication reviews compare to usual 
GP care36. Pharmacists are able to provide independent medication advice within a primary 
care setting making this role to be a simple extension to their cost saving role which their 
already undertake in the GP practice24. Pharmacists also prove to be valuable in 
management of more niche conditions such as insomnia37.  In a small Icelandic study38 with 
100 patients the pharmacist identified two drug therapy problems per patient. The most 
frequent problem was related to noncompliance, next was adverse drug reaction and the 
third was unnecessary medicines Almost all pharmacist interventions were accepted by the 
general practitioners  
 
Hazen et al’s39 systematic review investigated how the degree of integration of a non-
dispensing pharmacist into a healthcare team impacts medication related health outcomes 
in primary care.  Some pharmacists are fully integrated into the health care team, whereas 
others only temporarily provide a specific service. Common opinion is that integrated care 
for patients with chronic conditions may improve patient outcomes. Pharmacists have been 
shown to positively affect surrogate outcomes, such as blood pressure, glycaemic control 
and lipid goal attainment. Evidence of the effect of pharmacists on clinical endpoints, such 
as mortality, hospitalizations and health related quality of life, is less clear probably due to 
very heterogeneously defined pharmacy activities as well as strongly differing study 
settings. Most of the studies did not include prescribing pharmacists and the authors 
acknowledge that this might change health outcomes and needs further study. They also 
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acknowledge that pharmacists operating in isolation may negatively influence the quality of 
care and that studies highlight the importance of communication between pharmacists and 
GPs about the patients. The authors concluded that full integration adds value to patient-
centred pharmacy services, but not to disease-specific clinical pharmacy services and that to 
obtain maximum benefits of pharmacy services for patients with multiple medications and 
comorbidities, full integration of pharmacists should be promoted. 
Bush et al.40 attempted to characterise the breadth and volume of activity conducted by 
clinical pharmacists in general practice in an English Clinical Commissioning Group (CCG), 
and to provide quantitative estimates of both the savings in general practitioner (GP) time 
and the financial savings. This descriptive, retrospective, observational study analysed data 
collected by the CCG concerning the activity of pharmacists in GP practices during 2015. This 
descriptive paper based on routine data collection and relies on self-reporting of activity. 
Over the 9-month period for which data were available, the 5.4 whole time equivalent 
pharmacists operating in GP practices identified 23,172 interventions. 95% per cent of 
interventions identified were completed within the study period saving the CCG in excess of 
£1 000 000. However, there was no attempt to validate these interventions using for 
example an expert clinical panel.  During the 4 months for which resource allocation data 
were available, it was reported that the clinical pharmacists saved 628 GP appointments 
plus an additional 647 hours that GPs currently devote to medication review and the 
management of repeat prescribing. The authors conclude that the findings suggest that 
pharmacists in general practice in the CCG are able to deliver clinical interventions 
efficiently and in high volume, generating considerable financial returns on investment.  
 
Question 5: What are the barriers preventing successful implementation of this role? 
Funding is a very clear barrier to implementation. Depending on whom you ask, it seems 
that different stakeholders have different opinions on how to fund this initiative 41, 20, 29, 37. 
However, the initiative in the UK now has some clear funding models, while the 
sustainability of the models remains uncertain. Avery42 in a recent editorial suggested that 
while some general practices will be prepared to make a financial contribution unless a 
more generous approach is offered to general practices and the funding formula is changed 
the scheme may fail. He emphasised that although pharmacists may sometimes ease GP 
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workload the majority of the impact of practice-based pharmacists will be on quality and 
safety. 
 
Freeman et al 41 in their report of their Australian study have suggested a more ‘flexible’ 
model, to meet the needs of the community based on the individual skills or interests of GPs 
and pharmacists which in theory would allow customization of specific GP practices to 
match their population’s needs. The authors state, for example, uncontrolled asthma may 
be particularly common in the local population and thus the role of the pharmacist should 
be targeted toward this. There must also be core services provided by the pharmacist which 
allow a degree of consistency and enable large-scale and longitudinal review of the model 
and its benefits.  Uptake by patients poses as a common barrier in many studies 
reviewed18,3, patients do not realise that the service is available and what kind of care might 
be expected. The perceptions of other health care professionals can also be a barrier, 
particularly that of GPs29,31,43,44,45. Lack of infrastructure is also a common barrier, many 
general practices do not have a spare room to accommodate a pharmacist. Freeman47 
highlighted barriers to pharmacist integration such as medical culture ( he implied that this 
was due to “turf wars” and the doctor’s worrying about pharmacist taking over their roles)  
and remuneration.   
 
Question 6: What are the facilitators ensuring successful implementation of this role? 
More experienced pharmacists are considered to be more suited to the role34.  The authors 
highlight the importance of established relationships with doctors and patients stating that 
this would improve trust and allow for more inter-professional working. Cost saving is one 
of the reasons for the implementation, pharmacists have more time to evaluate medicine 
usage and reduce medicine wastage32. According to one editorial, independent prescribing 
pharmacists would benefit the GP practice more as the pharmacist can drastically reduce 
workload of GPs.  However, this remains to be measured in future studies. 47. If the 
implementation of pharmacists in general practices has resulted in overall health 
improvement this would naturally serve as a facilitator17,32, 34,35,36,37.  GPs benefit in multiple 
ways from the pharmacist presence. Pharmacists’ support and input are provided in a timely 
manner in instances when they may not have previously been sought, from clinical meetings 
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to incidental (‘corridor’) consultations. The practice pharmacist and GP relationship allows 
for advice tailored to the GP’s preferred style and immediate needs and enables ongoing, 
long-term collaboration on more challenging cases. So, If they have a good relationship with 
GP the pharmacist will know how the GP or practice operates and be able to tailor their 
advice and consultations accordingly. Further, GPs are more likely to enact advice from a 
trusted and respected colleague than recommendations from an external ‘contractor’.41 
 
Freeman46 highlighted facilitators to pharmacist integration such as remuneration and 
training, benefits of integration such as access to the patient’s medical notes, and potential 
funding models.  
 
Blondal et al. 22 concluded that direct contact between the pharmacist and GPs is better 
when working in the same building and that pharmacist’s access to medical records is 
necessary for optimal service. Pharmacists having other roles working in the practice (such 
as educating other health care providers), and the pharmaceutical care service needing to 
be well structured and streamlined to have benefits. However, the one thing the GPs 
interviewed in this Icelandic study mentioned most was the importance of the face-to-face 
communication. 
 
If integration of pharmacists into general practice is to be successful pharmacists need to 
develop their roles based on individual general practice needs rather than just assuming the 
national role description. For continuing success there will be challenges to overcome, such 
as defining standards for these new roles, and acceptance of patient-facing pharmacists by 
existing primary care team members and by patients. It is likely that the professional 
identity of pharmacists may change and general practice teams will need to find a new 
equilibrium. If these transitions can be facilitated, a bridge can be made between the 
patient and their medicines, enabling more optimum patient use of medicines.  
 
Realist analysis: what might work for whom? 
In answer to the realist question, “how do the key mechanisms of patient trust, GP 
confidence and pharmacist capability interact with contextual influences and the model of 
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delivery interact with one another to explain the successes and failures of pharmacists 
working in general practice?” five possible mechanisms were identified that might ensure 
the success of the initiative and the long-term viability of this role. The five mechanisms are 
the patient, the general practitioner, the pharmacist, the funding and the model of delivery.  
Mechanism 1: Patients  
From the research reviewed above independent prescribers are particularly valued by 
patients. Patients who have a better understanding of pharmacist services and have 
received those services and know what pharmacists are clinically able to do are more likely 
to see a pharmacist. They also consider that a pharmacist is capable of meeting their 
medication-related concerns, solving medicine related problems, improve their 
understanding of their medicines and improving their medicines adherence.  
Mechanism 2: General practitioners  
Overall the studies show mixed reactions from GPs, some are supportive while some remain 
more reserved about the idea. The GPs who support the implementation of pharmacists in 
GP practices tend to have a better knowledge of pharmacists mostly through working 
closely with pharmacists in the past. This experience allows the GPs to build trust and thus 
further professional relationship with the pharmacist. Direct contact and communication 
between the pharmacist and GPs is better when working in the same physical space where 
the pharmacist has access to medical records and is necessary for optimal service. 
Mechanism 3: Pharmacists  
Pharmacists must be able to gain the trust from key stakeholders, as mentioned earlier, 
both the patients and GPs who know more about pharmacists and have worked closely with 
them in the past are more welcoming to the idea of pharmacists in GP practices. 
Pharmacists taking on broader roles in the practice such as educating other health care 
providers also helps. Pharmacists needed to be visible, communicate well and be flexible 
and innovative. Mentoring and guided integration activities were helpful to facilitate 
integration practice but pharmacists might experience a variety of emotions while settling 
into the practice in the early months. Both the public and clinicians need to be educated on 
the abilities of pharmacists their training and capabilities. If there was increased awareness 
about pharmacists training and clinical expertise, then in theory it might increase the trust 
in pharmacists in general. Currently the NHS England initiative emphasises pharmacists to 
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be independent prescribing pharmacists or that they will be training to be independent 
prescribing pharmacists. This qualification further enhances the ability of pharmacists. Being 
an independent prescribing pharmacist might also increase trust as the pharmacist will be 
seen as more clinically capable.  
Mechanism 4: Funding  
Funding is probably the largest barrier to most public health policy implementation, this 
included. Currently the NHSE initiative has a clear path of funding for the first three years of 
implementation, but after three years, the general practice would have to fully fund the 
pharmacist.  
Mechanism 5: Model of delivery 
The model of delivery has to be flexible. Different general practices will have different 
populations and different focusses and needs. Therefore, they will require pharmacists to 
do different things. So pharmacists must be able to understand and adapt to the needs of 
the practice they are working in. This adaptability should not be the sole responsibility of 
the pharmacist. Although, the past experience of the pharmacist will heavily influence it. 
The GP practice should be able to provide the pharmacist with all the necessary induction, 
support, training and resources. The pharmacists must have a full presence in the practice 
and their roles must be clearly presented to patients.  
 
Discussion 
This study adds to the existing literature on pharmacists in GP practices by bringing it 
together and evaluating it in the form of a provisional realist analysis. Figure 2 portrays a 
provisional unifying model of the above five mechanisms and the contextual influences on 
them. Key findings from this analysis are firstly that patients value pharmacist independent 
prescribers and those patients whom have a better understanding of pharmacist services 
and what pharmacists are clinically able to do, are more likely to see a pharmacist. Secondly 
GPs are more likely to welcome pharmacists into the role if they have previous experience 
of working with them.  Thirdly pharmacists must gain the trust of GPs and patients. Fourthly 
adequate funding is essential, the NHSE initiative has a clear path of funding for the first 
three years of implementation in England, but after three years, the general practice would 
have to fully fund the pharmacist. Finally, the model of delivery of pharmacists’ roles in 
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general practice needs to be flexible and pharmacists need to adapt to the needs of 
individual practices and the practice should be able to provide the pharmacist with all the 
necessary induction, support, training and resources.    
 
Figure 2 Provisional unifying model  
 
Strength, limitations and future research design 
This review followed the international RAMESES guidelines for realist synthesis.11  Realist 
reviews consider what interventions will work well (and less well) for whom in which 
circumstances thus informing the development of future services and interventions in the 
future. This review included studies undertaken by different disciplinary teams with 
different goals and some of the studies were international, so although they inform the 
work in England, circumstances may have been different. We have begun to define and 
develop some the key ingredients for success for embedding pharmacists into GP practices.  
A limitation of this review is that the primary data were largely atheoretical and the majority 
of the studies used qualitative interview methodology or questionnaires to get perspectives 
from patients, GPs, practice managers and pharmacists.  It may have helped us to begin to 
develop our preliminary theory if more of the studies were less descriptive and had used 
theoretical frameworks or developed theory. 
 
While the majority of the studies focused on barriers and facilitators to the role of clinical 
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pharmacists in general practice most had very few details about the context of the role and 
if context had been included it would have better informed our realist review. In addition, 
further research is needed to assess the impact on patient outcomes, general practitioner 
workload, pharmacists’ experiences of starting and embedding this new role in general 
practice including experiences of training, support and mentoring.  There were no 
observational studies of how pharmacy work is conducted in practice. These limitations 
mean that the ideas proposed in our findings section are preliminary and should be subject 
to further testing as the role becomes more embedded.  
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